Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent form signed by the patient or patient's legal representative; also, if the patient is under the age of majority but capable of providing assent, signed assent from the patient~* Diagnosis of junctional or dystrophic EB.~* Patients who present with Hallopeau-Siemens subtype may be enrolled.~* At least one active, unroofed EB erosion on the limb or on the trunk.~* Lesion size 5 to 50 cm2, inclusive.~* Stable lesion present for 14-60 days before enrollment.~* More that one member in a family can be enrolled as long as that member is treated to a different cohort with an assurance that the study medication will not be shared.~* No clinically significant abnormalities (Grade 2 or higher on the National Cancer Institute \[NCI\] toxicity scale) on Screening laboratory tests, except for the following specific laboratory threshold result: albumin must be 2 g/dL or higher; hemoglobin must be 8 g/dL or higher.~Exclusion Criteria:~* Clinical evidence of local infection of the index (targeted) lesion.~* Use of any investigational drug within the 30 days before enrollment.~* Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.~* Use of systemic or topical steroidal therapy within the 30 days before enrollment.Inhaled steroids are allowed.~* Use of systemic antibiotics within the 7 days before enrollment.~* Current or former malignancy.~* Arterial or venous disorder resulting in ulcerated wounds.~* Diabetes mellitus.~* Pregnancy or breastfeeding during the study. (A serum pregnancy test will be performed at Screening for female patients of childbearing potential.)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
- 2 (Type: ACTIVE_COMPARATOR): Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days

Based on this trial design, predict the completion outcome and termination type (if applicable).